Aims and background. Italian performance in cancer research from 2000 to 2007 was assessed and compared to that of the other 19 wealthiest countries in the world which carry out the bulk of cancer research.
Introduction
It has long been recognized by the scientific community that it is important to have reliable ways to assess the quality of scientific research output 1 . However, the quantification and evaluation of research performance is fraught with difficulties and remains an area of animated debate and controversy 2 . Several studies indicate that various bibliometric measures are useful proxies of research quality and, in fact, bibliometric analyses are widely employed to assess scientific research performance 3 . Such assessment methods are today a fundamental part of the assessment of applications for research grants and allocation of funds for scientific research.
We believe that comparative bibliometric assessment of the research output by different countries can be useful in several ways: it can provide a measure of national performance useful for policy makers and those with funds to distribute and can also help scientists within individual countries to carry out more effective research.
We analyzed recent Italian performance in cancer research in comparison with that of the 19 richest countries worldwide, focusing on cancer research output over the years 2000 to 2007 in scientific journals indexed in the "oncology" category of Journal Citation Reports produced by Thomson Reuters -formerly known as Thomson Institute for Scientific Information 4 . Several bibliometric methods have been proposed for comparatively assessing cancer research performance [5] [6] [7] . For the purposes of this study, we assessed number of publications (quantitative measure) and impact factor (IF) as a quality indicator 8 . Although IF has been criticized 9 , it remains the most popular bibliometric indicator of the quality of the scientific articles. To take into account the effect of wealth and population size on the scientific output of the countries considered, the two indicators estimated for each country were corrected for gross domestic product (GDP) and population.
Materials and methods
Since cancer is mainly a disease of wealthy countries 10 , we assumed that cancer research is mainly performed by wealthy countries and therefore compared cancer research performance among the 20 richest countries as determined by the GDP in US dollars in 2007 ( Table 1) 11 . These countries are the USA, Canada, Mexico and Brazil (the Americas); China, Korea, Japan, India, and Indonesia (Asia); Germany, the United Kingdom, France, Sweden, the Netherlands, Belgium, Spain and Italy (Europe); and also Russia, Turkey and Australia.
We examined the 125 scientific journals indexed as "oncology" journals in Journal Citation Reports 4 , restricting our attention to four major categories of publication: articles, editorials, letters and reviews (subsequently referred to as publications). To identify these, we used the Scopus online database 12 . Scopus offers the broadest available coverage of scientific, technical, medical and social sciences literature, referring to 15,000 peer-reviewed journals from more than 4,000 publishers 12 . Scopus archives all the data in Medline published from 1995 on 12 .
For each archived publication, Scopus provides: author's surname, first name or initial; the affiliation of each author (typically a scientific institute, hospital or university department subsequently referred to as institute); the country of each institute and the International Standard Serial Number (ISSN) of the journal publishing the article.
Each publication was assigned to a country according to the institute to which each author was affiliated. To do this, the advanced search form of Scopus was used. On this form, the ISSN codes for the 125 "oncology" journals were used to select all publications in these journals over the time period considered. Next the AF-FILCOUNTRY(X) search field -where X was a given country -was used to select publications by country. The resulting publications were counted. This was done for each country in turn. Using this method, a publication with authors from various countries was assigned 134 A MICHELI, F DI SALVO, C LOMBARDO ET AL to each country represented, and a publication with several authors from a single country was assigned to that country only once. As noted, we calculated two country indicators: (a) the number of publications (NP) attributed to each country for each year of the study period, and (b) the total IF (TIF) achieved by each country for each year of the study period. To estimate the latter, we used as starting point the IF quoted for each journal reported in the 2006 edition of Journal Citation Reports 4 . We then applied this IF value to all publications of each journal, irrespective of year of publication. Finally, we summed the IF values of all included publications for each country for each year thus producing TIF for each country and for each year.
The resulting country indicators for each year of the study period were adjusted for wealth by dividing by GDP to produce NP/GDP (number of publications per billion US$) and TIF/GDP (TIF per billion US$). To adjust for population, NP and TIF were divided by the population producing NP/pop (number of publications per million inhabitants) and TIF/pop (TIF per million inhabitants). GDP and population for each year were obtained from the World Economic Outlook databank of the International Monetary Fund ( Table 1) 11 . All indicators were calculated per year; data and indicators are presented by two-year periods. In 2006-2007,the US had the highest GDP, which accounted for 32% of the total GDP of all 20 countries considered. Italy was 7 th with 5% of the total GDP and 13 th in terms of population (Table  1) 11 . In 2006-2007, China had the highest population.
Results

Numbers of publications
The numbers of cancer publications attributable to the 20 countries are shown in Table 2 When the number of publications was adjusted by GDP (Table 3) 4, 11 , the ranking compared to unadjusted Articles, editorials, letters and reviews published in "oncology" journals as defined by the Journal Citation (Table 3) 4, 11 and in the unadjusted analyses, throughout the study period.
When the number of publications was adjusted for population (Table 4) 
Impact of publications
The TIF of the publications produced increased for all 20 countries over the study period. 
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Discussion
We found that the number of cancer publications produced by Italy increased over the study period -as did the numbers produced by the other 19 countries con-sidered. By this quantitative measure, Italy remained stably in 5 th position, whereas the US was always in first position ( Table 2) 4 . In 2006-2007, Italy ranked 7 th in terms of GDP and 13 th in terms of population (Table 1) , and thus by the quantitative measure, Italy did better Table 4 3  7  11  11  10  9  18  16  4  5  9  10  6  6  7  4  12  12  15  15  17  18  19  19  13  13  16  17  8  8  2  2  14  14  5  3  1  1  20  20 than might be expected from its GDP and populationwhich seem to influence the output of oncological research 3 . This impression is confirmed by the GDP and population-adjusted data, where Italy was in 4 th position in [2006] [2007] (Table 3) 4, 11 in the GDP-adjusted ranking and in 5 th place in the population-adjusting ranking in 2006-2007 (Table 4 ) 4, 11 . However, it should be noted that over the entire study period Italy lost ground in the GDP-adjusted ranking and gained ground in the population-adjusted ranking. These findings suggest that, in terms of number of publications, Italy benefited from the aging of its population -Italy has one of the oldest populations worldwide 13 . A similar picture emerged for Italy when the quality of cancer research publications was considered. In 2006-2007, Italy was in 5 th place for crude TIF (with the US at 1 st ) (Figure 1 4 ) , in 4 th place for GDP-adjusted TIF (with Sweden at 1 st ) (Figure 2 ) 4 , and in 6 th place for population-adjusted TIF (Sweden at 1 st ) ( Figure 3) 4 . Over the entire study period, Italy was stable in terms of crude TIF and population-adjusted TIF but declined somewhat in terms of GDP-adjusted TIF. When we performed an ancillary analysis to compare country performance in terms of mean TIF (defined as TIF/NP), we found that Italy ranked quite low, indicating that the mean impact in terms of quality of Italian publications is low. This result was expected because Italian cancer research is known to be at a low level in terms of translational effects. There were problems with this analysis, however, because the indicator usually varied markedly and was particularly unstable (high variance) for countries with a small number of publications.
-Mean number of yearly cancer publications* in each two-year period per million inhabitants (NP/Pop) for each country ranked by 2006-2007 GDP 11
Previous publications, which used different methods and different data, have indicated that Italy performs reasonably well, both in terms of the number and quality of cancer publications, compared to expectations in terms of its GDP and population size. Using cancer research publications indexed in Thomson Scientific's Web of Science 14 and also oncology-related papers published in other scientific journals, Lopez-Illescas et al. 15 investigated the performance of European Union countries (EU-15), Norway, China, India, Japan, the US and South Korea. In 2006, Italy ranked 3 rd in terms of number of articles published and 8 th in terms of relative journal IF − an index calculated by dividing the average IF of the journal in which a country published by the world average IF 15 . In 2008, Tas published a quantitative analysis by country of papers published in meeting abstracts of the American Society of Clinical Oncology, the European Society for Medical Oncology and their journals (Journal Clinical Oncology and Annals of Oncology). It was found that Italy was the second largest contributor to American Society of Clinical Oncology meeting abstracts, the largest contributor to European Society for Medical Oncology meeting abstracts, and the second largest contributor to both official journals combined over the period 2000 to 2006 16 . Ugolini and Mela 7 ana-lyzed European (EU-15 plus Norway) oncological research performance in 1995 by examining articles in oncological journals indexed in Current Contents/Life Science and Current Contents/Clinical Medicine 7 . Italy ranked in 2 nd place in terms of number of papers. In a previous report, Mela et al. 3 analyzed papers published in 1995 in the oncological journals listed by the Institute for Scientific Information (Philadelphia, USA). In terms of number of publications, Italy was in 4 th place among the 25 countries considered 3 . A study that analyzed the literature pertaining to molecular epidemiology of cancer published in 1995-2004 17 placed Italy 5 th of 35 countries in quantitative terms, whereas a study that analyzed clinical cancer research publications by 25 countries in 1995-1999 placed Italy in 2 nd place in quantitative terms 5 .
Relatively good Italian performance in cancer research is unexpected because of the fairly low levels of public spending on research 18 and the fact that the proportion of researchers in the population is also low 19 . In 2000, there were 2.8 scientists per 1,000 inhabitants compared to 5.4 per 1,000 inhabitants in the EU15 19 . Unfortunately, specific information on cancer researchers does not appear to be available. Availability of indicators such as the ratio of investment in cancer research to GDP, or the number of cancer researchers in the population, would have enabled a more precise interpretation of Italian performance. Instead, we had to make do with GDP-and population-adjusted estimates. The relatively good Italian performance in cancer research may be partly explained by the consistent support of Italian charities and non-profit organizations that direct funds to cancer research projects. For example, the Italian Association for Cancer Research 20 has been a major supporter in Italy of basic cancer research, and most likely also of basic biology research. More recently, some Italian bank foundations are also playing an important role.
We used data provided by the Scopus database, which covers all data archived in Medline after 1995, hence covering the period 2000-2007 we considered 12 . We also performed an analysis of papers by country extracted from Medline database and obtained results broadly similar to those presented here (data not shown).
We used the standard counting procedure 6 in which a single publication may be counted more than once, depending on how many countries are represented by the authors' institutes (but with no country counted more than once). Other studies assigned the publication to the country of the corresponding author (usually, but not always, the first author) 3 , thus assigning each publication to one country only, which is generally -but not necessarily -the country of the institute of the person mainly responsible for the study. Both procedures have advantages and disadvantages. It is important, however, to know the exact procedure used in order to be able to interpret results and to understand differences in re-sults from one study to another. We limited our analysis to journals of the oncology category of Journal Citation Reports 4 published from 2000 through 2007. We are aware that important contributions to cancer research are published in basic science journals, general journals, and those concerned with specific organs or systems. However, although we certainly missed some cancer publications, we avoided the erroneous inclusion of non-oncological papers and also avoided making subjective choices as to which publications should be included.
We applied the IF for 2006 4 , irrespective of the actual year of the publication. Other authors have followed approaches in which an IF specific for each year was applied. However, our approach is sensitive of the scientific value of past publications -since the real value of a publication usually becomes evident some years after publication -although it tends to underestimate the value of recent publications. In this respect, we would emphasize that the intention of the present study was to evaluate Italian performance in comparison with other countries, and it is unlikely that this comparison was appreciably affected by our approach.
To investigate possible difficulties related to the method we used to assign papers to authors, authors to institutes, and institutes and authors to countries, we carried out ancillary analyses of authors and of institutions. Authors are usually recognized by surname plus the initial of the first name. Classification errors may occur if a person changes surname (particularly women who change their surname on marriage, as required by law in some countries) or if several persons have the same surname and initial. We searched the Scopus author field for "Micheli A" (Andrea Micheli is the first author of the present paper), finding that 251 articles in the entire Scopus databank (no selection for year or scientific domain) were attributed to this "author." For some of these articles, Scopus gave precise first name information (Alessia, Adriana, Adolph, Andrea, Alessandro, etc) and articles were excluded for which the first known name was not "Andrea", which left 184 articles. Comparing these 184 articles with those in Andrea Micheli's CV [personal communication], only 120 items matched. So 64 articles in the Scopus data-bank referred to a "Micheli A" who is not the Andrea Micheli of the present article. Furthermore, three articles actually authored by Andrea Micheli were erroneously assigned to "Micheli Adriana".
An Institute may change its name or may be referred to by more than one name. Andrea Micheli's institute (briefly, the INT) is referred to variously in the scientific literature (Istituto Nazionale Tumori Milano, National Cancer Institute of Milan, Istituto Tumori Milan). Examination of the INT website indicated that in 2007 authors affiliated to the INT published 327 articles that should all be archived in Scopus. Scopus uses two affiliation codes for the INT and by applying both codes Sco-pus only recognized 307 of the 327 articles. These investigations suggest that there are quite serious misclassification and missing data problems, and that these can adversely affect the accuracy of bibliometric studies. However, we assume that most of these errors were random and affected all countries more or less to the same extent.
To conclude, we have found that Italy's performance in cancer research performance over the last 8 years was better than expected considering its GDP and population. Nevertheless, we found some evidence of a decline in performance over the study period, and we discussed other problems affecting Italian cancer research because of the low level of mean TIF. This result should encourage Italian scientists and Italian policy makers to find ways to improve the situation, especially with the goal of transferring this good performance in terms of production of new diagnostic and therapeutic tools which will benefit cancer patients.
